Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study

BACKGROUND: Although olaparib, the first poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor approved, has been used in routine clinical practice for over three years, little has been published on its uptake, utilization patterns, and clinical outcomes. OBJECTIVE: To examine real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Irene, Wettermark, Björn, Bergfeldt, Kjell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297279/
https://www.ncbi.nlm.nih.gov/pubmed/30446872
http://dx.doi.org/10.1007/s11523-018-0604-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297279/
https://www.ncbi.nlm.nih.gov/pubmed/30446872
http://dx.doi.org/10.1007/s11523-018-0604-z

Ejemplares similares